drugset
drugset / Trial / NCT03605862

Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection

NCT03605862 ↗

Phase 3 Completed 1756 enrolled Romark Laboratories L.C.
RandomizedParallel-groupTriple-blindTreatment

Summary

Trial to evaluate efficacy and safety of nitazoxanide in the treatment of colds due to Enterovirus/Rhinovirus infection

Timeline

Start
2018-09-11
Primary completion
2019-02-04
Completion
2019-02-04

Drugs

EvaluationDrugModalityDoseRoute
Comparator Nitazoxanide Other / unclassified 600 mg Oral

Indications

common cold enterovirus infectious disease